Nasal COVID-19 Vaccine Based on WashU Technology to Enter U.S. Clinical Trials
February 07, 2025
February 07, 2025
ST. LOUIS, Missouri, Feb. 7 -- The Washington University School of Medicine issued the following news release:
By Tamara Schneider
A nasal vaccine for COVID-19 - based on technology developed at Washington University in St. Louis - is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug application from Ocugen, Inc. was approved by the Food and Drug Administration (FDA). Ocugen, a U.S.-based biotechnology company, licensed the innovativ . . .
By Tamara Schneider
A nasal vaccine for COVID-19 - based on technology developed at Washington University in St. Louis - is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug application from Ocugen, Inc. was approved by the Food and Drug Administration (FDA). Ocugen, a U.S.-based biotechnology company, licensed the innovativ . . .